Clinical Trial Update: Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing pembrolizumab versus placebo in patients with resected high-risk stage II melanoma reports safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-06-24